Postmastectomy lymphangiosarcoma-temporary response to cyclophosphamide chemotherapy in 2 cases

Tong, David; Winter, Janet

doi:10.1002/bjs.1800610118

Cited by 4 publications

(1 citation statement)

References 14 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been isolated reports of cure it is more realistic to consider median survival time as an indicator of prognosis. Combination chemotherapy, delivered either systemically 6 , 7 or by limb perfusion, 8 only minimally increases median survival time to 26.5 months. Radiotherapy has no place in treatment.…”

Section: Discussionmentioning

confidence: 99%

A Rare Late Complication of Breast Cancer Treatment

Clements

Kirk

Spence

1993

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY In 1948 Stewart and Treeves recognised and described six cases of lymphangiosarcoma arising in the oedematous upper limb of patients who had previously undergone radical mastectomy and radiotherapy for breast carcinoma.1 The incidence of lymphangiosarcoma in such patients is 0.45%2 and is uniformly aggressive and fatal, with a 5‐year survival of less than 5% regardless of the treatment modality.3 We present a case report to increase the clinical awareness of this rare and fatal iatrogenic complication occurring subsequent to breast cancer treatment, and speculate on ways of improving survival.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Late Complication of Breast Cancer Treatment

Clements

Kirk

Spence

1993

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

Chemotherapy for postmastectomy lymphangiosarcoma

Yap

McBride

et al. 1981

Cancer

View full text Add to dashboard Cite

Twenty-two patients with postmastectomy lymphangiosarcoma have been seen at M. D. Anderson Hospital during the past 20 years. Of these, 13 received chemotherapy, either regionally, systemically, or both. Six patients were treated with regional chemotherapy using either methotrexate alone, a combination of melphalan, nitrogen mustard, and actinomycin D, or a combination of melphalan with nitrogen mustard or actinomycin D; 3 achieved a partial or complete response. Eleven patients received 19 trials of systemic chemotherapy; one complete and seven partial responses were observed, giving an overall response rate of 42% (8/19). Responses occurred with 5-fluorouracil, methotrexate, a combination of vincristine, actinomycin D, and cyclophosphamide, and a combination of Adriamycin and dacarbazine with or without vincristine. The median survival time of the six patients who responded to at least one chemotherapeutic trial was 26.5 months compared with four months for the five patients who failed to respond. These data indicate that chemotherapy may play a significant role in the treatment of patients with this rare but distinctive tumor. Cancer 47:853-856, 1981. YMPHANGIOSARCOMA OCCURRING AFTER RADICAL

show abstract